NZ Keytruda Funding Knockback Sparks Drug Cost Row
This article was originally published in Scrip
Executive Summary
The ongoing debate over the costs and benefits of new medicines for cancer and other diseases has been rekindled in New Zealand after the funding agency, Pharmac, said it would need more evidence of the benefits of Merck & Co's Keytruda (pembrolizumab) in advanced melanoma before it could recommend it for funding over other medicines with a better cost-effectiveness profile.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.